Directive transparence : information réglementée

Paris (France), Cambridge (USA), 14 February 2020 - 8am CET, Biophytis SA
(Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company with a
primary focus on the development of its lead drug candidate, Sarconeos (BIO101)
for the treatment of neuromuscular diseases, announced the completion of a
private placement of new shares allowing it to achieve a capital increase of
approximately EUR3.3 million. The transaction was conducted via a private
placement, which was carried out on 12 February 2019 after the market closed.

The common shares were purchased by institutional European and U.S. investors,
most of them previously invested in Biophytis

Terms of private placement
This private placement resulted in the issuance of 12,394,071 new common shares
via a capital increase, without preferential subscription rights, or 31.6% of
the shares outstanding after the transaction. For illustration purposes, a
shareholder holding 1% of the share capital of the Company prior to this
capital increase will experience a decrease in its holding to approximately
0.684%, assuming no purchase by it of new common shares in this private
placement.

The price of the new common shares to be issued is EUR0.27 per share following
an accelerated book building exercise. This price corresponds to a 29.5%
discount to the weighted average Biophytis stock price over the last 10 trading
sessions prior to private placement. Biophytis estimates the gross proceeds of
the issuing to be
EUR3,346,399.17 million.

Following the capital increase, the shareholding structure will be as
follows:

Use of funds
Biophytis will use the net proceeds of the capital increase to strengthen its
financial resources, in particular for the preparation of the MYODA clinical
study in Duchenne Muscular Dystrophy (DMD), for which Sarconeos (BIO101)
obtained an IND from the FDA in December 2019. This capital increase, along
with the other financing instruments already in place, allows the company to
secure its financial position beyond the next 12 months.

Settlement-delivery and listing of new shares
The settlement-delivery of the securities will take place on or about February
19, 2020, subject to the usual conditions. The new common shares should be
admitted to trading on the regulated Euronext Paris market under the existing
ISIN code of Biophytis common shares by no later than February 20, 2020. The
new common shares, with a face value of EUR0.20 euro, will rank equally with
the existing common shares of Biophytis.

This private placement was made pursuant to Article L. 411-2 II of the Monetary
and Financial Code under the 12th resolution of the Extraordinary General
Meeting of Shareholders held on August 8, 2019.

The decision to conduct this capital increase was made by the Company's Board
of Directors, at a meeting on 12 February 2020. This capital increase was made
by issuing new common shares with the removal of the preferential right of
subscription of shareholders in accordance with Article L. 225-136 of the Code
of Commerce (by private placement of less than 20% of the company's share
capital).

In accordance with Article 211-3 of the AMF General Regulation, this offer of
financial securities did not require a prospectus subject to the AMF visa.

Detailed regulatory information regarding the Company are available in the 2018
Annual report, accessible on its website: http://www.biophytis.com/ , including
the entirety of chapter 4 regarding risks

Stanislas Veillet, President and CEO of Biophytis, said: "We are pleased to
announce that we have successfully received commitments for a capital increase
of EUR3.3 million. This allows Biophytis to reinforce its financing structure,
and in particular for the preparation of the MYODA clinical study in Duchenne
Muscular Dystrophy (DMD), for which Sarconeos (BIO101) obtained an IND from the
FDA in December. I want to thank our investors who have been following us for
years and have not hesitated to invest again in Biophytis at a 73% premium to
last week's lowest share price"

The private placement is led by H.C. Wainwright & Co. as the exclusive
placement agent in the United States and Banque Delubac and Cie - CIB as an
advisor and global coordinator of the transaction.

****

About BIOPHYTIS
Biophytis SA is a clinically staged biotechnology company specializing in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, particularly
neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is
being developed for the treatment of Duchenne myopathy (DMD) for which the
company received IND status by the U.S. Food and Drug Administration (FDA) in
December 2019.

The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

Warning
This press release contains forward-looking statements. While the Company
considers its projections to be based on reasonable assumptions, these
forward-looking statements may be called into question by a number of hazards
and uncertainties, so that actual results may differ materially from those
anticipated in such forward- looking statements. For a description of the risks
and uncertainties likely to affect the results, BIOPHYTIS' financial position,
performance or achievements and thus cause a change from the forward-looking
statements, please refer to the "Risk Factors" section of the Company's Equity
Admission Prospectus for listing on the Euronext Growth market in Paris filed
with the AMF and available on the AMF (www.amf-france.org) and BIOPHYTIS
websites ( www.biophytis.com).

This press release, and the information contained in it, does not constitute an
offer to sell or subscribe, nor the solicitation of a purchase or subscription
order, of BIOPHYTIS shares in any country. The elements contained in this
communication may contain forward-looking information involving risks and
uncertainties. The Company's actual achievements may differ materially from
those anticipated in this information due to different risk and uncertainty
factors. This press release was written in French and English; If there is a
difference between the texts, the French version will prevail.